Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

June 8, 2018: By Jon Swedien

Cincinnati Eye Institute, with the help of Denver-based Revelstoke Capital Partners, has formed a new management services organization that will seek to acquire other ophthalmic practices around the nation, CEI announced May 24.

“Our goal, with the launch of CEI Vision Partners, is to become one of the nation’s largest and most comprehensive eye care management companies,” said CEI’s board chair, Robert Foster, MD.

CEI Vision Partners is CEI’s parent company. Founded in 1945, CEI is currently a group of more than 60 practicing ophthalmologists and optometrists that maintains 14 clinical centers and three ambulatory surgical centers.

Foster declined to say how much Revelstoke invested, the Cincinnati Business Courier reported.

CEI officials said the group has the infrastructure required to scale up to offer services to other eye care groups, even if they don’t formally merge, the Courier reported.

Revelstoke helps businesses execute acquisition growth strategies. It has raised about $1.1 billion of equity and has completed 42 acquisitions since it was formed in 2013, according to CEI.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023